معرفی
Ghaith Abu-Zeinah, M.D. is an Assistant Professor of Medicine at Weill Cornell Medical College and Assistant Attending Physician at NewYork-Presbyterian Hospital. He specializes in Myeloproliferative Neoplasms (MPNs) through the Richard T. Silver MPN Center, maintaining a dual clinical-research practice focused on MPN therapeutics and malignant stem cell targeting.
Education:
- M.D. with academic distinction from Weill Cornell Medical College, Cornell University (2013)
- Residency in Internal Medicine at NewYork-Presbyterian Hospital/Weill Cornell Medicine (2016)
- Fellowship in Hematology/Oncology at NewYork-Presbyterian Hospital/Weill Cornell Medicine (2019)
His research bridges translational science and clinical care, with emphasis on developing curative MPN treatments through malignant stem cell targeting. Current work leverages machine learning for risk prediction models and automated extraction of hematopathology data. Clinical expertise spans Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, and Chronic Myeloid Leukemia.
Recent publications demonstrate leadership in MPN clinical trials (EXCEED-ET, ECLIPSE-PV, PARADIGM-PV), pharmacovigilance studies, and pandemic-era hematology research through the EPICOVIDEHA registry. His work frequently addresses treatment safety, risk stratification, and novel therapeutic approaches in MPNs.
No specific scientific awards are listed in available materials, though his bio notes he has received several awards for his work and presented at major conferences including the International Congress on MPNs and American Society of Hematology.
Dr. Abu-Zeinah maintains active clinical practice at the Richard T. Silver MPN Center (520 East 70th Street, New York) and leads research funded by the American Society of Hematology (2024-2027) on predicting disease progression in Polycythemia Vera using machine learning. His external collaborations include consulting roles with Dr AZ Consulting LLC and Slingshot Insights Inc.
